Since we could not observe any correlation between CK20 mRNA expression and OS in EC patients with neoadjuvant treatment, it can be speculated that neoadjuvant therapy either eliminated CK20 positive CTC and DTCs or promoted an epithelial–mesenchymal transition (EMT) by which carcinoma cells can lose epithelial markers such as cytokeratin [55]. This evidence concerns the gene KRT20 and carcinoma.